Novo Nordisk's late stage diabetes candidate semaglutide ... in controlling glucose levels and body weight. The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed ...

which mimics the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) hormones, patients had a 20.2% reduction in weight by week 72 compared with a 13.7% reduction in ...

The research will focus on the use of GLP-1 receptor agonist medications and their possible cognitive benefits in aging ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

Eighteen studies examined the effect of GLP-1RAs on weight loss, glucose control ... known as Victoza), semaglutide (Ozempic or Wegovy), exenatide (Byetta or Bydureon), and dulaglutide (Trulicity).

Innovent announces phase 3 study of mazdutide in Chinese adults with overweight or obesity (GLORY-1) published in the NEJM: San Francisco, US Tuesday, May 27, 2025, 11:00 Hrs [IST ...

Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic ...

this is the first study directly comparing the dual agonist glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide 1 (GLP-1) tirzepatide with GLP-1 semaglutide. The results suggest ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...